Aurobindo’s unit IX clears USFDA audit
Aurobindo Pharma’s Unit 9 has successfully completed the USFDA audit with no Form 483 observations, as per the media sources. Unit IX is a Cephalosporin API manufacturing facility located in Medak.
Aurobindo has a form 483 observations at Unit 4, which are procedural in nature. There are no data integrity issues and we believe it should get cleared soon.
Aurobindo Pharma Ltd is currently trading at Rs602.25 up by Rs8.4 or 1.41% from its previous closing of Rs593.85 on the BSE.
On a one MISSED CALL on @9039006355 you can have your Free Trials for two days in Share Market so why are you waiting for, Hurry up! SUBSCRIBE US >> Bonaz Capital